INTRODUCTION
Pregnant women are vulnerable to malaria infection. Pregnancy-associated malaria can causes adverse pregnancy outcomes including abortion, preterm birth, low birth weight, congenital malaria, intrauterine growth retardation (IUGR), anemia and metabolic disorders that increase the risk of disease in later stages of child development. 1 Numerous studies have reported on the prevalence of peripheral parasitaemia and placental parasitaemia in the area stable endemic malaria transmission in Africa. The median prevalence of maternal malaria infection (defined as an infection of peripheral or placenta) for all gravid was 27.8%. The highest risk of maternal malaria infection occurred during the second trimester of pregnancy while at the early postpartum period study showed inconsistent. 2 Plasmodium falciparum is the most common Plasmodium species in Indonesia. 3 A study in Timika-Papua, an area of multidrug-resistant to P. vivax and P. falciparum, show both species are associated with substantial morbidity. 4 P. vivax and P. falciparum have been previously reported to be chloroquine resistant in Papua. 5 Any attempt for malaria prevention in Indonesia is controlled by Annual Parasite Incidence (API) since 2007. This policy requires that every case of malaria infection has to be confirmed with blood smear microscopy and treated with artemisinbased combination therapy (ACT). 6 ACT significantly reduced the vertical transmission risk of malaria in Papua. 7 Other studies demonstrated that a single dose of artesunate monotherapy was effective and had no adverse effect in the second and third trimester of pregnancy. 8 This study is aimed to determine the effect of artesunate therapy in peripheral parasitaemia on second and third trimester of pregnancy with P. falciparum infection and their newborns after treatment.
METHODS
This prospective cohort study was conducted in health facilities in Sorong, West Papua from September 2015 to February 2016. Pregnant women infected with falciparum malaria in the second and third trimester and their newborns from Waisai General Hospital, Timika General Hospital, Sele Be Solu Hospital and Makbon Community Health Center were enrolled in this study. Parasitaemia in capillary blood from pregnant women and placenta and cord blood from newborns were diagnosed by blood smear microscopy and a Rapid Diagnostic Test (RDT). Pregnant women were administered with artesunate monotherapy 200 mg (4 mg/kg) per oral once daily for 7 days. Newborns weight was measured at delivery; birth weight <2500 g defined as low birth weight. Pregnant women with complicated malaria, have taken other anti-malarial drugs prior to data collection, and unwilling to join the study were excluded.
McNemar test was used to analyze the effect of artesunate therapy on peripheral parasitaemia. The study protocol was approved by the Health Research Ethics Committee of Faculty of Medicine, Hasanuddin University.
RESULTS
This study involved 40 pregnant women with falciparum malaria. After being administered with artesunate therapy, 82.5% (33/40) malariainfected pregnant women had negative parasitaemia although 17.5% (7/40) of these women had positive parasitaemia (17.5%). These differences were statistically significant (p<0.001). The results are shown in Table 1 . Parasitaemia positive was found 10% (4/40) positive in placenta and 7.5% (3/40) in umbilical cord from newborns of malaria-infected women treated with artesunate (Table 2 ). Seventy percent of the newborns in this study born had normal birthweight (Table 3) . 8 A previous study has found that anti-malaria artesunate monotherapy in the second and third trimester of pregnancy has a better efficacy compared to 6 doses of artemetherlumefantrine. 9 Artesunate may also delay the onset of hemolysis in severe malaria. 10 Artesunate is sodium salt of the hemisuccinate ester of artemisinin. It is soluble in water but has poor stability in aqueous solutions at neutral or acid pH. It is rapidly absorbed with peak plasma levels occuring after 1.5 hours for oral, rectal and 2 hours to 0.5 hours for injections. 11 Artemisin and its derivatives (artesunate, artemether, dihydroartemisinin) are rapidly hydrolyzed in vivo into the activity dihidroartemisin with equivalent antimalaria. 12 Four possible mechanisms of artemisin action against plasmodia when artemisin activated through disconnection intrinsic bond peroxide are line error detoxify heme groups, the induction of the alkylation process translational control of protein tumor (PfTCTP) and other proteins, inhibition of PfATPase6 enzyme activity and interference the function of Plasmodium mitochondria. 13 In this study, we found that the parasites remained in peripheral blood after being administered with artesunate therapy in pregnant women and in the placenta as well as umbilical cord of newborns through RDT and microscopic examination. The prevalence of parasitaemia varied. This might be a result of differences in the definition of congenital malaria, maternal immunity level, types of blood samples examined (peripheral blood or cord blood of neonates), the expertise in microscopic examination, the parasite detection methods (microscopic or PCR) and differences in geographical factors of malaria-endemic areas. 14 The prevalence of malarial parasite is different with different examination methods. A previous study indicated that the prevalence of malarial infection in the placenta with RDT, microscopy and PCR was 95%, 70% and 100% while in the umbilical cord was 10%, 12.8% and 95%, respectively. 15 Fetal exposure to malarial parasites in utero has been proposed to modify the immune response of newborns, increasing their susceptibility to symptomatic malaria infections at birth and later in life. [16] [17] [18] Low birth weight is one of the adverse outcomes in pregnancy-associated malaria in all levels of endemicity. Pregnant women with falciparum and vivax malaria are at higher risk for low birth weight. Low birth weight is associated with the mechanical obstruction of malaria parasite that attached to chondroitin sulphate A (CSA) receptors in the syncytiotrophoblast of the placenta that impaired circulation from mother to fetus and affect the transport of oxygen and nutrients. But research by Pongtasik conducted in malaria endemic areas of East Nusa Tenggara expression CSA in pregnant women with placental malaria had no correlation with malaria infection of peripheral blood postpartum. 19 Primigravida has been associated with increased risk of malarial infection. In areas where P. falciparum is endemic, parity reduced vulnerability to malaria infection during pregnancy. This is due to lack of antibodies that can blocked adhesion of erythrocytes-malaria infected to the placenta CSA. 20 CSA adhesion phenotype specific to placental parasites by the var gene expression (var2 csa). 21 However, recent study suggested that CSA expression in the placenta not associated with parity and low birth weight. 22 The majority of the newborns whose mothers were administered with artesunate during pregnancy had normal weight. The risk of low birth weight increased 2-fold in the area of stable transmission if the mother suffered from placental malaria with the largest effect on primigravidae. Odds ratio (OR) of low birth weight 2-7 times higher in primigravidae compared to multigravidae. 1 The median reduction in birthweight in the reviewed studies was 150 g for P. falciparum or mixed infections and 108 g for P. vivax malaria. Malaria reduces birthweight occurs mainly in first pregnancies with P. falciparum but also in subsequent pregnancies, and even with one episode of P. vivax or P. falciparum. Both symptomatic and asymptomatic malaria episodes increase the risk of low birth weight, although symptomatic infections in pregnancy might have a larger effect than asymptomatic disease, particularly on premature delivery. 23 
CONCLUSION
In brief, we found artesunate monotherapy could reduce peripheral parasitaemia in the second and third trimester of pregnancy in pregnant women Vol 5 
Effect of artesunate in pregnant women 137 with malarial infection. Newborns whose mothers were received artesunate monotherapy had normal weight.
